DOCSLIB.ORG

Dunigan, Jay T., Ed. Drug Abuse, Rs. Resource Guide For

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dunigan, Jay T., Ed. Drug Abuse, Rs. Resource Guide For DOCUMENT RESUME ED 056 894 SE ,)'12 711 AUTHOR Dunigan, Jay T., Ed. TITLE Drug Abuse,rs. Resource Guide forEducators. INSTITUTION Capital District RegionalSupplementary Educational Center, Albany, N.Y. PUB DATE Apr 71 NOTE 132p. AVAILABLE FROMCapital District RsEc, 301Sand Creek Road, Albany, New York 12205 ($2.00) EDRS PRICE KF-$0.65 HC-$6.58 DESCRIPTORS *Bibliographic Citations; *DrugAbuse; Drug Addiction; *Drug Education; HealthEducation; Reference Materials; *Resourceguides ABSTRACT Providing educators with acomprehensive resource document that will be useful inresearching and developing effective drug abuse education programsis the intent of this document. As an orientation to its use, two terms arediscussed at length--addiction and habituation. In additiois., someof the most commonlyused drugs are described.Bibliographic references comprisethe major portion of the bcok. Citations are givenfor books, lay periodicalarticles, professicnal journal articles,pamphlets and booklets, reports, indexes, ab,stracts, bibliographies,glossaries, audio visual aids, and agencies offering drugabuse information. Supplementarynarrative material in several areaselaborates on;(1) a chronology of important federal legislationregarding narcotics and dangerous legal considerations as to druginvolvement by students in drugs, (2) a schools,(3) program suggestionsfor drug education programs, (4) list of stimulant and depressz4ntdrugs, and (5)a comprehensive glossary of slang and scientificdrug terms. (1311) performed pursuant to a Grant from the U. S.Office of The mirlrk presented or reported herein was herein do Education; Pe6artment of Health, Educationand Welfare. Howe?sr, the opinions expressed official not necessarily reflect tho position orpolicy of thU. S. Office of Education, and no be inferred. .-endorsement by the U. S. Office of Education should 2 DRUG ABUSE A RESOURCE GUIDE FOR EDUCATORS Compiled and Edited by Jay T. Dunigan April 1971 yelgOe CAPITAL DISTRICT REGIONAL SUPPLEMENTARY EDUCATIONAL CENTER 381 SAND CREEK ROAD, ALBANY, N.Y. 12205 (518) 459-2266 EOARD OF DIREugga F. Donald Myers, President John Bach Cecil S. Mapes Donald Schein Franklin B. Clark George Maybury Amato Semenza Carl Cramer Raymond O'Brien Ferford A. Smith Homer P. Dearlove hester Ostrander Kenneth A. Smith James J. Drislane John Panek Dudley P. VanArnam Edwin Dunmire Joseph Reilly Lewis P. Welch John Lynch William Rochelle Leslie Wiley Rev. Thomas J. Maloney John Ryan Donald Willets REGIONAL CENTER STAFF Alfred J rno4 Direc Nicholas M. DeLuca Assistant Director for Redeign Jay T. Dunigar. Assistant Director for Administr.:5con Russell C. Fo:'-)es Assistant Director for Plalning Edward L. Welch Center Assote SECRETARIAL STAFF MI . Marion Fere-lon Miss Gail Rauch Mrs, Diane WI ler PREFACE It is our intention in preparing thisdocument to provide educators in thisregion with a compre- hensive resource document that will beuseful in researching and developing effective drugabuse education programs. The phenomenon of drug abuse has found most educatorsinsufficiently prepared to face the problem. Most of the educators we have been associated with have expressed adesire to upgrade their personal level ofinformation regarding drug abuse and about resourcesdealing with the topic. This publication is in direct response to that kind of request. Its existence is attributable to the diligent efforts of Jay Dunigan. Those who know the tremendous number of hours needed toproperly search out, review, compile and edit such a comprehensive work can truly appreciate thethanks we owe and extend to Mr.Dunigan. In addition, we wish to thank Miss Gail Rauch and Mrs.Diane Wheeler for their help in typing and preparingthe manu- script for publication. On behalf of the Board of Directors, and the Center staff, I take f-reat pleasure inpresenting this resource work to the many educatorsin this region who stimulated its existence. Alfred J. Cali Director Albany, New York April 1971 TABLE OF CONTENTS Introduction 1 BIBLIOGRAPHICAL PEFERENCFS Books 13 Lay Periodical Articles 29 Professional Journal Articles 41 Pamphlets and Booklets 55 Reports 65 Indexes, Abstracts and Bibliographies 71 Glossaries 77 udio Visual Aides 79 Agencies Offering Drug Abuse Information 85 ANCILLARY MATEPIALS Drug Abuse And The Law 89 Legal Considerations 91 Program Suggestions 97 Stimulant and Depressant Drugs: Lists of, 105 Coul!.ty Community Mental Health Agencies Serving Capital-District Region 107 Narcotic Guidance Councils Serving Capital District Region 109 Glossary of Slang and Scientific Terms 115 INTRODUCTION Drug abuse is not a new phenomenon. It has been with us since the dawn of mankind. Why then has it only now, in the past few months been elevated to the list of our nation's top priority problems? Until recently drug abuse was a problem which affected mainly our urban poor adults and older youths. As a nation we were concerned but not upset. Things are different now. Drug abuse has broken out of the black and brown ghettos. It now lives and lurks in all of our lives. Those most seriously affected today are our youth. Those least able to cope with the problem are most often hit by it. As a partial orientation to the use of this resource volume, we would like to present a disc..,:lsion of two terms critical to .1111 understanding of drug abuse and then a few words about the most commonly abused drugs. You will notice the absence of discussion on the three most popular and widely used drugs in America, namely alcohol, nicotine and caffeine. The two critical terms to be discussed are frequently used interchangeably when in fact they are quite different. They are addiction and habituation. Addiction is a physiological dependence characteri-.ed by two factors: tolerance and withdrawal. An addicted person becomes sensitized to the addictive substance and thereby needs proportionately greater amounts of the drug in order to acheive the desired effects. Secondly, the addictive substance effects certain critical bodily processes in such a way that it replaces or greatly diminishes these processes. Upon discontinuance 2 of the drug a gap is created. The body is left without the effect of the drug and without the critical processesthat the drug has replaced. This gap is characterized by severe physiological disturbances in normal functioning of the body. At best the condition is extremely painful and at worst death canbe the result. This is what is meant by the term witadrawal. Habituation is a psychological dependence. Neither tolerance nor withdrawal need beevidenced for habituation to take place. There ie a strong mental yearning and to some degree aphysical craving for the drug. One doesn't need the habituatingsubstance in order to function but does want it very badlyfor any number of reasons. Let's look at the process of becoming addicted toHeroin by way of example. Let's assume that you have neverused this drug for any purpose. You don't need it to go on living. You don't even want it because you don't knowwhat it's like. However, you suspect that Heroin mightbe quite nice because so manypeople have gotten hooked (addicted) on it. However, you know that you won't become addicted because you knowthe dangers and will only try enough of it to find out whatit's like and then stop, Well, it's available from a friend at work Orfrom a store keeper you know or some how, so you decide to try someand guess what! It's free! Yes! Your friend gives it to you to try. You have no problem because you aren'tgoing to inject it. All you do is sniff it up into your nose. It really is quite pleasant. It lessens the tensions of yourday; even makes you feel like the old you. Of course you do get a littlesleepy from it but that's to be expected from animportant busy person like yourself. It's easy to see now that you canhandle this drug and that it's not as dangerous as everyoneis trying to make people believe. Of course, you aren't stupid. You know, if you were to start injecting it into yourveins, that you would soonbecome addicted and that would be horrible. But, it will never happen to you. One reason that you could neverbecome addicted is because you hate needles. Now that you know how to handlehorse (Heroin) you decide that it won't hurt to snort (sniff) some oncein a while. So you do. Now it's not free however. Only the sample was free. You are now habituated to the drug but not addicted. You don't need it and there is no tolerance and would be noproblem of withdrawal if you decided to stop now. But why stop? If you have no addiction problem why not use it in acontrolled way and get the fun outof it. Make no mistake, it is fun. It is really quite nice. *3 3 You begin snorting with your friends on anoccasional basis. After a few months things are not all that theyused to be. They (the suppliers in New York) are diluting theseuff so much now, that in order to get the sameeffect, you have to snort twice as much as when you first started. It's not that you are building a tolerance to the drug. It's just that the pushers (sellersI in New York City are getting greedierand so you have to compensate for their greed. All along your friends, who also use (takedrugs), have been trying to get you to shoot up (inject) but you aretoo smart for that. But there is a short cut you could teke. You've seen Bob skin popping (injecting the heroin subcutaneouslyrather than intravenously). Here is a way you could really helpyourself out and at the same time lessen the chances of ycurbecoming addicted. Everybody knows that if you take the drug this way youneed less than if you snort it and so your chances ofgetting hooked are much less.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • University Microfilms
    INFORMATION TO USERS This dissertation was produced from a microfilm copy of the original document. While the most advanced technological means to photograph and reproduce this document have been used, the quality is heavily dependent upon the quality of the original submitted. The following explanation of techniques is provided to help you understand markings or patterns which may appear on this reproduction. 1. The sign or "target" for pages apparently lacking from the document photographed is "Missing Page(s)". If it was possible to obtain the missing page(s) or section, they are spliced into the film along with adjacent pages. This may have necessitated cutting thru an image and duplicating adjacent pages to insure you complete continuity. 2. When an image on the film is obliterated with a large round black mark, it is an indication that the photographer suspected that the copy may have moved during exposure and thus cause a blurred image. You w ill find a good image of the page in the adjacent frame. 3. When a map, drawing or chart, etc., was part of the material being photographed the photographer followed a definite method in "sectioning" the material. It is customary to begin photoing at the upper left hand corner of a large sheet and to continue photoing from left to right in equal sections with a small overlap. If necessary, sectioning is continued again — beginning below the first row and continuing on until complete. 4. The majority of users indicate that the textual content is of greatest value, however, a somewhat higher quality reproduction could be made from "photographs" if essential to the understanding of the dissertation.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Iain Sinclair and the Psychogeography of the Split City
    ORBIT-OnlineRepository ofBirkbeckInstitutionalTheses Enabling Open Access to Birkbeck’s Research Degree output Iain Sinclair and the psychogeography of the split city https://eprints.bbk.ac.uk/id/eprint/40164/ Version: Full Version Citation: Downing, Henderson (2015) Iain Sinclair and the psychogeog- raphy of the split city. [Thesis] (Unpublished) c 2020 The Author(s) All material available through ORBIT is protected by intellectual property law, including copy- right law. Any use made of the contents should comply with the relevant law. Deposit Guide Contact: email 1 IAIN SINCLAIR AND THE PSYCHOGEOGRAPHY OF THE SPLIT CITY Henderson Downing Birkbeck, University of London PhD 2015 2 I, Henderson Downing, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. 3 Abstract Iain Sinclair’s London is a labyrinthine city split by multiple forces deliriously replicated in the complexity and contradiction of his own hybrid texts. Sinclair played an integral role in the ‘psychogeographical turn’ of the 1990s, imaginatively mapping the secret histories and occulted alignments of urban space in a series of works that drift between the subject of topography and the topic of subjectivity. In the wake of Sinclair’s continued association with the spatial and textual practices from which such speculative theses derive, the trajectory of this variant psychogeography appears to swerve away from the revolutionary impulses of its initial formation within the radical milieu of the Lettrist International and Situationist International in 1950s Paris towards a more literary phenomenon. From this perspective, the return of psychogeography has been equated with a loss of political ambition within fin de millennium literature.
    [Show full text]
  • 2019 Complete Law Book
    Message from the Board Chairman Welcome to the Gem State! Thank you for downloading the Idaho Pharmacy Law Book, which compiles select state laws relevant to the practice of pharmacy in or into Idaho. The Board acknowledges that changes in the education and training of pharmacists, as well as rapid advancements in the technology environment, have required a change in approach to regulating the practice of pharmacy. The Board continues to embrace those changes and the growth of our profession. Rule 27.01.01.100 provides guidance to licensees and registrants as they determine whether a specific act is permissible. First, a licensee or registrant should consider whether the act is expressly prohibited by any state or federal law. If an act is not expressly prohibited, the licensee should consider whether: • The act is consistent with the licensee or registrant’s education, training or practice experience; and • Performance of the act is within the accepted standard of care that would be provided in a similar setting by a reasonable and prudent licensee or registrant with similar education, training and experience. Two questions that may help licensee or registrant’s successfully navigate this change in approach from prescriptive rules to professional judgment follow: 1. If someone asks why I made this decision, can I justify it as being consistent with good patient care and with law? 2. Would this decision withstand a test of reasonableness (e.g., would another prudent pharmacist make the same decision in this situation)? You should consult an attorney if you have questions as to the legality of your actions under the laws and rules regulating pharmacy in the State of Idaho.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Top of Page Interview Information--Different Title
    Oral History Center, The Bancroft Library, University of California Berkeley Oral History Center University of California The Bancroft Library Berkeley, California Joey Terrill Joey Terrill: At the Forefront of Queer Chicano Art Interviews conducted by Todd Holmes in 2017 Interviews sponsored by the J. Paul Getty Trust Copyright © 2017 by J. Paul Getty Trust Oral History Center, The Bancroft Library, University of California Berkeley ii Since 1954 the Oral History Center of the Bancroft Library, formerly the Regional Oral History Office, has been interviewing leading participants in or well-placed witnesses to major events in the development of Northern California, the West, and the nation. Oral History is a method of collecting historical information through tape-recorded interviews between a narrator with firsthand knowledge of historically significant events and a well-informed interviewer, with the goal of preserving substantive additions to the historical record. The tape recording is transcribed, lightly edited for continuity and clarity, and reviewed by the interviewee. The corrected manuscript is bound with photographs and illustrative materials and placed in The Bancroft Library at the University of California, Berkeley, and in other research collections for scholarly use. Because it is primary material, oral history is not intended to present the final, verified, or complete narrative of events. It is a spoken account, offered by the interviewee in response to questioning, and as such it is reflective, partisan, deeply involved,
    [Show full text]
  • WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 36/84 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61P 31/22 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61K 45/06 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/NL20 14/050780 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 13 November 2014 (13.1 1.2014) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/903,430 13 November 2013 (13. 11.2013) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: RJG DEVELOPMENTS B.V.
    [Show full text]
  • Ideas About Drug Abuse: Proceedings from the Institute for Drug Education at Syracuse
    DOCUMENT RESUME ED 065 744 AC 012 353 AUTHOR Reagan, Michael V., Ed. TITLE Ideas About Drug Abuse: Proceedings from the Institute for Drug Education at Syracuse. INSTITUTION Syracuse Univ., N.Y. Continuing Education Center for the Public Service. PUB DATE Jan 72 NOTE 268p. EDRS PRICE MF-$0.65 HC-$9.87 DESCRIPTORS *Conference Reports; Counselor Role; *Drug Abuse; *Drug Addiction; *Drug Education; Evaluation; *Information Dissemination; Institutes (Training Programs); Interviews; Participant Involvement; School Role; State Laws IDENTIFIERS *Syracuse University ABSTRACT The Institute for Drug Education at Syracuse (IDEAS) University provided its 750 participants (teachers, students, counselors, and parents) with an array of information essential to them in understanding and coping with the drug dilemma in their local schools. This book is a compilation of what the staff felt was the best of the materials prepared for this conference. The chapters of the book are: 1. The Human Price of Drug Abuse; 2..The Art of Not Listening; 3. Excerpts from New York State Laws.Concerning Dangerous Drugs; 4. Excerpts from: Drug Abuse--Conflicting Theories and Interventions; 5. Source Book--Program Development, Inservice Education; 6. Parameters of Inservice Training; 7. Local Government Perspective on Drug Abuse; 8. Interview with Annette; 9. Interview with Willis; 10. Interview with Kevin and Mary; 11..Interview with Dr. Wayne 0. Evans; 12. Value Orientations and Treatment Strategies; 13. Some Cognitive Concepts of Team; 14. Considerations in the Development
    [Show full text]
  • Appendices Feb 2010 Inclusion of Cobalt and 2019 Fei Prohibited
    APPENDIX 2 CLASSIFICATION OF PROHIBITED SUBSTANCES 1. This classification describes the types of Prohibited Substances and places same in specific categories. The list shall be published on the Club’s Notice Board. CLASS I Drugs that have the greatest pharmacological potential to affect the racing performance of a horse and which have no accepted medical use in a racehorse. These include substances which are potent stimulants of the Central Nervous System (CNS). Examples of drugs in this Class include, but are not limited to: Amphetamines, fentanyl, etorphine, cocaine, morphine, meperidine, opiates, opium derivatives, synthetic opiods, psychoactive drugs. CLASS II Drugs that have a high pharmacological potential for affecting the racing performance of a horse. These include: (i) substances which are pharmacologically active in altering the cons (ii) substances which are not generally accepted as therapeutic agents in the racing horse; and (iii) substances, some of which may have legitimate use in equine medicine but should not be found in the racing horse, such as injectable local anaesthetics. 1 Groups of drugs in this Class include, but are not limited to: (a) Opiate partial agonists, or agonistsantagonists; (b) Non-opiate psychotropic drugs, which may have stimulant, depressant, analgesic or neuroleptic effects; (c) Miscellaneous drugs which might have a stimulant effect on the CNS; (d) Drugs with prominent CNS depressant action; (e) Antidepressant and antipsychotic drugs, with or without prominent CNS stimulatory or depressant effects; (f) Muscle blocking drugs which have direct neuromuscular blocking action; (g) Local anaesthetics which have a reasonable potential for use as nerve blocking agents (except procaine); and (h) Snake venom and other biologic substances which may be used as nerve blocking agents.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Control Substance List
    Drugs DrugID SubstanceName DEANumbScheNarco OtherNames 1 1-(1-Phenylcyclohexyl)pyrrolidine 7458 I N PCPy, PHP, rolicyclidine 2 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine 9663 I Y PEPAP, synthetic heroin 3 1-[1-(2-Thienyl)cyclohexyl]piperidine 7470 I N TCP, tenocyclidine 4 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine 7473 I N TCPy 5 13Beta-ethyl-17beta-hydroxygon-4-en-3-one 4000 III N 6 17Alpha-methyl-3alpha,17beta-dihydroxy-5alpha-androstane 4000 III N 7 17Alpha-methyl-3beta,17beta-dihydroxy-5alpha-androstane 4000 III N 8 17Alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene 4000 III N 9 17Alpha-methyl-4-hydroxynandrolone (17alpha-methyl-4-hyd 4000 III N 10 17Alpha-methyl-delta1-dihydrotestosterone (17beta-hydroxy- 4000 III N 17-Alpha-methyl-1-testosterone 11 19-Nor-4-androstenediol (3beta,17beta-dihydroxyestr-4-ene; 4000 III N 12 19-Nor-4-androstenedione (estr-4-en-3,17-dione) 4000 III N 13 19-Nor-5-androstenediol (3beta,17beta-dihydroxyestr-5-ene; 4000 III N 14 19-Nor-5-androstenedione (estr-5-en-3,17-dione) 4000 III N 15 1-Androstenediol (3beta,17beta-dihydroxy-5alpha-androst-1- 4000 III N 16 1-Androstenedione (5alpha-androst-1-en-3,17-dione) 4000 III N 17 1-Methyl-4-phenyl-4-propionoxypiperidine 9661 I Y MPPP, synthetic heroin 18 1-Phenylcyclohexylamine 7460 II N PCP precursor 19 1-Piperidinocyclohexanecarbonitrile 8603 II N PCC, PCP precursor 20 2,5-Dimethoxy-4-(n)-propylthiophenethylamine 7348 I N 2C-T-7 21 2,5-Dimethoxy-4-ethylamphetamine 7399 I N DOET 22 2,5-Dimethoxyamphetamine 7396 I N DMA, 2,5-DMA 23 3,4,5-Trimethoxyamphetamine
    [Show full text]